Compare PRSU & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSU | GLUE |
|---|---|---|
| Founded | 1926 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 960.2M | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | PRSU | GLUE |
|---|---|---|
| Price | $33.44 | $23.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $31.67 | $29.50 |
| AVG Volume (30 Days) | 263.8K | ★ 2.9M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 902.95 | N/A |
| EPS | ★ 10.75 | 0.25 |
| Revenue | ★ $441,143,000.00 | $181,538,000.00 |
| Revenue This Year | $26.24 | $84.02 |
| Revenue Next Year | $8.08 | N/A |
| P/E Ratio | ★ $3.27 | $95.32 |
| Revenue Growth | 4.63 | ★ 1112.27 |
| 52 Week Low | $26.66 | $3.50 |
| 52 Week High | $42.43 | $25.77 |
| Indicator | PRSU | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 45.36 | N/A |
| Support Level | $33.00 | N/A |
| Resistance Level | $34.49 | N/A |
| Average True Range (ATR) | 0.95 | 0.00 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 45.35 | 0.00 |
Pursuit Attractions and Hospitality Inc is an attractions and hospitality company that owns and operates a collection of inspiring and unforgettable experiences at iconic destinations across the United States, Canada, and Iceland. Its elevated hospitality offerings include point-of-interest attractions and distinctive lodges, as well as integrated restaurants, retail options, and transportation that allow visitors to discover and connect with breathtaking national parks and renowned travel locations.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.